FDA Rejects Regenxbio's Gene Therapy for Hunter Syndrome After Clinical Hold

FDA issues Complete Response Letter rejecting RGX-121 gene therapy for Hunter syndrome, citing trial design concerns. Regenxbio plans to resubmit with additional data.